Both in Biotechnology
Monte Rosa Therapeutics vs Prime Medicine
Over the past year GLUE returned −12.1% and PRME returned +11.1%; their daily moves had a correlation of 0.27.
GLUE −12.1% PRME +11.1%Growth of $1, one year, split-adjusted
| Metric | GLUE | PRME |
|---|---|---|
| Price | $10.61 | $5.07 |
| Market cap | $905.2M | $918.7M |
| Today | +1.92% | +11.32% |
| 1 month | +7.5% | +44.7% |
| 6 months | −48.0% | +48.5% |
| Year to date | −32.3% | +46.0% |
| 1 year | −12.1% | +11.1% |
| Revenue growth (YoY) | −61.3% | +3.5% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −483.9% | −3649.0% |
| P/E (TTM) | — | — |
| Price / sales | 31.5× | 225.6× |
| Net cash | $621.1M | $95.1M |
| Dividend yield | — | — |
| Volatility (60d) | 52.7% | 113.5% |
| Short % of float | 41.9% | 34.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).